Appili Therapeutics Management

Management criteria checks 2/4

Appili Therapeutics' CEO is Don Cilla, appointed in Nov 2022, has a tenure of 1.58 years. total yearly compensation is CA$608.27K, comprised of 71.2% salary and 28.8% bonuses, including company stock and options. directly owns 0.062% of the company’s shares, worth CA$3.00K. The average tenure of the management team and the board of directors is 1.6 years and 5.1 years respectively.

Key information

Don Cilla

Chief executive officer

CA$608.3k

Total compensation

CEO salary percentage	71.2%
CEO tenure	1.6yrs
CEO ownership	0.06%
Management average tenure	1.6yrs
Board average tenure	5.1yrs

Recent management updates

Recent updates

Market Sentiment Around Loss-Making Appili Therapeutics Inc. (TSE:APLI)

Mar 24

Appili Therapeutics Inc.'s (TSE:APLI) Shift From Loss To Profit

Dec 09

CEO Compensation Analysis

How has Don Cilla's remuneration changed compared to Appili Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-CA$4m
Dec 31 2023	n/a	n/a	-CA$5m
Sep 30 2023	n/a	n/a	-CA$8m
Jun 30 2023	n/a	n/a	-CA$8m
Mar 31 2023	CA$608k	CA$433k	-CA$9m
Dec 31 2022	n/a	n/a	-CA$10m
Sep 30 2022	n/a	n/a	-CA$11m
Jun 30 2022	n/a	n/a	-CA$20m
Mar 31 2022	CA$747k	CA$477k	-CA$25m
Dec 31 2021	n/a	n/a	-CA$27m
Sep 30 2021	n/a	n/a	-CA$28m
Jun 30 2021	n/a	n/a	-CA$19m
Mar 31 2021	CA$627k	CA$170k	-CA$14m

Compensation vs Market: Don's total compensation ($USD444.57K) is above average for companies of similar size in the Canadian market ($USD175.36K).

Compensation vs Earnings: Don's compensation has been consistent with company performance over the past year.

CEO

Don Cilla

1.6yrs

Tenure

CA$608,271

Compensation

Dr. Donald D. Cilla, also known as Don, Jr., PharmD, MBA, serves as Chief Executive Officer, President and Director at Appili Therapeutics Inc. since November 13, 2022 and served as its Chief Development O...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Donald Cilla	CEO, President & Director	1.6yrs	CA$608.27k	0.062% CA$ 3.0k
Kenneth Howling	Chief Financial Officer	2.6yrs	CA$522.62k	no data
Gary Nabors	Chief Development Officer	1.2yrs	no data	no data

1.6yrs

Average Tenure

Experienced Management: APLI's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Donald Cilla	CEO, President & Director	1.6yrs	CA$608.27k	0.062% CA$ 3.0k
Lidija Marusic	Board Observer	5.1yrs	no data	no data
Prakash Gowd	Director	less than a year	no data	no data
Lynn Silver	Member of Advisory Board	no data	no data	no data
Dean Shinabarger	Member of Advisory Board	no data	no data	no data
Brian Bloom	Director	9.1yrs	CA$19.50k	no data
Juergen Froehlich	Independent Director	4.4yrs	CA$60.13k	no data
Armand Balboni	Chairman of the Board	5.3yrs	CA$741.29k	no data
Theresa Matkovits	Lead Independent Director	5.7yrs	CA$84.63k	no data
Sridhar Narayan	Member of Scientific Advisory Board	no data	no data	no data

5.1yrs

Average Tenure

58yo

Average Age

Experienced Board: APLI's board of directors are considered experienced (5.1 years average tenure).

Appili Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Less than half of directors are independent

Appili Therapeutics Inc., Annual General Meeting, Sep 27, 2023

Appili Therapeutics Inc. Announces Executive Appointments

Appili Therapeutics Inc. Promotes Don Cilla to the Position of Chief Executive Officer

Appili Therapeutics Inc., Annual General Meeting, Sep 22, 2022

Appili Therapeutics Inc. Appoints Rochelle Stenzler as Board of Directors

Recent updates

Adivir, Inc. entered into a definitive agreement to acquire Appili Therapeutics Inc. (TSX:APLI) for $6.7 million.

Less than half of directors are independent

Appili Therapeutics Inc. Secures Commitment for Second Stage of Funding for ATI-1701 from U.S. Air Force Academy

Appili Therapeutics Announces U.S. FDA Approval of Likmez (ATI-1501) Metronidazole Oral Suspension

Appili Therapeutics Inc., Annual General Meeting, Sep 27, 2023

No longer forecast to breakeven

Appili Therapeutics Inc. and Saptalis Pharmaceuticals LLC Announce That FDA Accepts the ATI-1501 NDA

Appili Therapeutics Inc. Announces Executive Appointments

Appili Therapeutics Inc. Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole

Appili Therapeutics Inc. Promotes Don Cilla to the Position of Chief Executive Officer

Appili Therapeutics Inc., Annual General Meeting, Sep 22, 2022

No longer forecast to breakeven

Appili Therapeutics Inc. announced that it expects to receive $10 million in funding from Defense Threat Reduction Agency

Appili Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 4.5 million.

Appili Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 4.5 million.

Price target decreased to CA$0.25

Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis

Appili Therapeutics Inc. announced that it expects to receive CAD 4.504032 million in funding from Long Zone Holdings Inc.

Appili Therapeutics Inc. Announces Over $10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701

Price target decreased to CA$1.27

Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan/Reeqonus for the Treatment of Mild-to-Moderate COVID-19

Appili Therapeutics Inc. announced that it has received $1 million in funding from FUJIFILM Toyama Chemical Co., Ltd.

Appili Therapeutics Inc. Announces Completion of Patient Enrollment for Avigan Reeqonus Viral Shedding Sub- Study for Mild-To-Moderate Covid-19 Patients

Price target decreased to CA$2.12

Appili Therapeutics Inc. announced that it has received CAD 3.395 million in funding from The Lind Partners, LLC

Appili Therapeutics Inc. announced that it expects to receive CAD 3.5 million in funding from The Lind Partners, LLC

Forecast breakeven pushed back to 2023

Appili Therapeutics Inc. Expands Preseco Clinical Trial of Avigan®/Reeqonus™ for Mild-To-Moderate Covid-19 Patients into Mexico and Brazil

Independent Data Safety Monitoring Board Recommends Appili Therapeutics Inc. Complete its Phase 3 Avigan®/Reeqonustm Trial for Mild- To-Moderate COVID-19 Patients

Independent Data Safety Monitoring Board Recommends Appili Therapeutics Complete its Phase 3 Avigan/Reeqonus Trial for Mild-to-Moderate COVID-19 Patients

Market Sentiment Around Loss-Making Appili Therapeutics Inc. (TSE:APLI)

New 90-day low: CA$0.96

Earnings beat expectations, revenue disappoints

Appili Therapeutics Inc. Appoints Rochelle Stenzler as Board of Directors

Appili Therapeutics Provides Enrollment Update for Its Phase 3 PRESECO Trial Evaluating the Oral Antiviral Favipiravir as an Early Treatment in COVID-19

New 90-day low: CA$1.02

Appili Therapeutics Inc.'s (TSE:APLI) Shift From Loss To Profit

First Patient Dosed in Appili Therapeutics’ Phase 3 Clinical Trial of Avigan® Tablets (Favipiravir) for the Treatment of COVID-19 in the United States

Appili Therapeutics Inc Announces Initiation of its Phase 3 Post Exposure Prophylaxis for Covid-19 (Pepco) Study to Evaluate Avigan® Tablets (Favipiravir) in the Prevention of Covid-19

Earnings miss expectations

New 90-day high: CA$1.50

Appili Therapeutics Joins Dr. Reddy's, Global Response Aid, and Fujifilm in Advancing Avigan Tablets for the Potential Treatment of Covid-19

Appili Therapeutics Inc. Announces Appointment of Don Cilla as Chief Development Officer, Effective November 1, 2020

Appili Therapeutics Inc. Announces Updates for the Continued Development of its ATI-1701 Biodefense Vaccine Program

New 90-day high: CA$1.19

New 90-day low - CA$0.86

Price target lowered to CA$3.03

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age